ONC Stock BeOne Medicines AG
STRONG BUY US · NasdaqGSGlobal oncology growth and improving sentiment make this a liquid biotech standout.
Future value: $436.46 (+17.69%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Positive momentum and broad oncology catalysts.
- ▸Above 50-day MA (+2.15%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (86.8% of range) — strength
Is ONC a buy right now?
Trend: ONC is trading above the 50-day average (+2.15%), RSI 39 — neutral momentum, with a 3-month return of +12.23%.
Valuation & quality: BeOne Medicines AG trades on a trailing P/E of 66.3, forward P/E 35.5, PEG 0.80, price-to-book 8.10; fundamentals show net margin 10.7%, return on equity 14.7%, revenue growth 29.6% year on year.
Analyst consensus: 27 analysts have a mean 12-month price target of $436.46 (+17.7% vs the last close; range $370.00 – $528.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Global oncology growth and improving sentiment make this a liquid biotech standout.
Computed from end-of-day data; not personal advice.
Our track record with ONC
Our simulated $10,000 funds have traded ONC 1 time, 1 position still open.
| Fund | Bought | Sold | Return |
|---|---|---|---|
| US High-risk | 2026-09-22 @ $365.67 | Still held · $377.63 | +3.27% |
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -6.30% | -0.60% | -2.50% | -1.00% | +10.90% | +13.80% | +1.80% | +1.30% |
Fundamentals
Analyst price target
Technical signals
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Sector: Healthcare · Industry: Biotechnology · Switzerland · 12,000 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.